How $25 Million in AI Funding Could Reshape Drug Discovery Dynamics
Converge Bio has secured $25 million in Series A funding, a development that signals a transformative shift in how artificial intelligence (AI) is poised to reshape the pharmaceutical industry. This substantial investment, spearheaded by Bessemer Venture Partners, underscores the growing urgency for biotech firms to harness AI technologies to revolutionize drug discovery—a process historically mired…